论文部分内容阅读
[目的]探讨LOXL2在肺腺癌中的表达情况及与临床病理特征预后意义。[方法]采用免疫组化染色(Immunohistochemical staining,IHC)的方法检测60对配对的肺腺癌及癌旁组织中LOXL2蛋白的表达水平,并根据免疫组化染色评分判断LOXL2蛋白的表达强度,分析LOXL2蛋白表达与肺腺癌临床病理特征以及预后的相关性。[结果]LOXL2蛋白在癌组织中显著性高表达。LOXL2蛋白在肺腺癌组织中主要定位于细胞核。细胞核LOXL2高表达与肺腺癌的淋巴结转移(P=0.025)、TNM分期(P=0.031)相关,并是肺腺癌差预后的独立预测因子(P=0.028)。[结论]细胞核LOXL2蛋白的高表达与肺腺癌患者的差预后相关,LOXL2可以作为肺腺癌患者的一种新的预后生物指标和潜在的治疗靶点。
[Objective] To investigate the expression of LOXL2 in lung adenocarcinoma and its clinical significance. [Method] The expression of LOXL2 protein in 60 paired lung adenocarcinoma tissues and paracancerous tissues was detected by Immunohistochemical staining (IHC) method. The expression intensity of LOXL2 protein was determined by immunohistochemical staining. Correlation of LOXL2 Protein Expression with Clinicopathological Characteristics and Prognosis of Lung. [Results] LOXL2 protein was highly expressed in cancer tissues. LOXL2 protein is mainly located in the nucleus in lung adenocarcinoma. High LOXL2 expression in nucleus was correlated with lymph node metastasis (P = 0.025) and TNM stage (P = 0.031) in lung adenocarcinoma and was an independent predictor of poor prognosis in lung adenocarcinoma (P = 0.028). [Conclusion] The high expression of LOXL2 protein in nucleus is related to the poor prognosis of patients with lung adenocarcinoma. LOXL2 may serve as a new prognostic biomarker and potential therapeutic target for patients with lung adenocarcinoma.